# Greenhill R6

## 1

#### Interpretation – Marijuana isn’t a Medicine. The aff must de

Mosley 20, Mark. "Medical Marijuana Is a Dangerous Lie." Emergency Medicine News 42.8 (2020): 2-3. (Dr. Mark Mosley is an emergency medicine physician in Wichita, Kansas and is affiliated with Wesley Healthcare Center. He received his medical degree from University of Oklahoma College of Medicine and has been in practice for more than 20 years.)//Elmer

**Marijuana is not a medical drug.** It is a **slang term for** a **plant of the Cannabis family that contains more than 60 different cannabinoid substances and more than 80 biologically active compounds**. Using the term marijuana in place of THC would be like using willow tree in place of acetylsalicylic acid, the active ingredient in aspirin.

#### FDA and CDC definitions prove.

CDC ’18 (CDC; Centers for Disease Control and Prevention; 3-7-2018; “**Is marijuana medicine**?”; CDC; <https://www.cdc.gov/marijuana/faqs/is-marijuana-medicine.html>; Accessed: 9-4-2021; AU)

The marijuana plant has chemicals that may help symptoms for some health problems. More and more states are making it legal to use the plant as medicine for certain conditions. But there isn’t **enough research** to show that the whole plant works to treat or cure these conditions. Also, the U.S. Food and Drug Administration (FDA) **has not recognized** or **approved** the marijuana plant **as medicine**. Because marijuana is often smoked, it can damage your lungs and cardiovascular system (e.g., heart and blood vessels). These and other damaging effects on the brain and body could make marijuana more harmful than helpful as a medicine. Another problem with marijuana as a medicine is that the ingredients aren’t exactly the same from plant to plant. There’s no way to know what kind and how much of a chemical you’re getting.

#### **Violation – the resolution calls for reductions on IP protections for medicines, but the aff prevents future patents for cannabis-derived products.**

#### Vote neg for limits and ground. Expanding the definition of “medicine” to anything that could be used in a medical setting floods the neg with cases to prep for – everything from new methods of chemo to upgrading stethoscopes becomes topical.

#### Precision outweighs – anything else justifies the aff arbitrarily jettisoning words in the resolution at their whim which decks negative ground and preparation because the aff is no longer bounded by the resolution, no one researches non WTO states since they aren’t in the resolution which is the only stasis point.

#### At best – they’re extra-T since Cannabis isn’t intrinsically medicinal, it just has medicinal uses so they would reduce Recreational Marijuana patents too which isn’t topical and explodes limits.

Johnson 20 Ian Johnson 1-20-2020 "Cannabis Patents 2000 – 2019: Trends Following Legalization" <https://plantlaw.com/2020/01/20/cannabis-trends-medical-recreational/> (Registered Patent Agent, Plant & Planet Law Firm)//Elmer

These findings correspond to the overall increase in **cannabis-related patents** and demonstrate that the recreational patent sector is growing at an even greater rate than cannabis patents generally. This supports the theory that recreational markets and expansion of legal personal use of cannabis have resulted in an increase in patent activity in the industry. Again, publication totals are not necessarily the most accurate reflection of patent behavior by cannabis businesses. Therefore, it is useful to examine filing and provisional trends for recreational patents. These results are subject to the same 18-month delay problems noted above, and therefore actual and projected values are provided. Using actual filing data for 2017, there has been a 181% increase in filing activity since 2012. Using projected filing data for 2019, there has been a 257% increase in recreational filing activity since 2012. Using actual priority claims for 2017, there has been a 196% increase in provisional filing activity since 2012. Using projected priority claims for 2019, there has been a 289% increase in recreational provisional filing activity since 2012. The following charts demonstrate recreational filing trends from 2012 to 2019. Patents **that could be classified as recreational** **made up approximately 53% of all filings** between 2000 and 2011. However, **following legalization** the percent of patents and applications considered recreational has **increased to** approximately **77% of filings in 2018**. The chart below demonstrates the growth of the recreational sector’s share of cannabis patent activity.

#### Fairness and education are voters – debate’s a game that needs rules to evaluate it and education gives us portable skills for life like research and thinking.

#### Drop the debater – a) they have a 7-6 rebuttal advantage and the 2ar to make args I can’t respond to, b) it deters future abuse and sets a positive norm.

#### Use competing interps – a) reasonability invites arbitrary judge intervention since we don’t know your bs meter, b) collapses to competing interps – we justify 2 brightlines under an offense defense paradigm just like 2 interps.

#### No RVIs – a) illogical – you shouldn’t win for being fair – it’s a litmus test for engaging in substance, c) chilling effect – forces you to split your 2AR so you can’t collapse and misconstrue the 2NR, d) topic ed – prevents 1AR blipstorm scripts and allows us to get back to substance after resolving theory

#### Evaluate T before 1AR theory – a) norms – we only have a couple months to set T norms but can set 1AR theory norms anytime, b) magnitude – T affects a larger portion of the debate since the aff advocacy determines every speech after it.

## 2

#### Interpretation: “medicines” is a generic bare plural. The aff may not defend WTO member nations reducing intellectual property protections for a subset of medicines.

#### The upward entailment test and adverb test determine the genericity of a bare plural

Leslie and Lerner 16 [Sarah-Jane Leslie, Ph.D., Princeton, 2007. Dean of the Graduate School and Class of 1943 Professor of Philosophy. Served as the vice dean for faculty development in the Office of the Dean of the Faculty, director of the Program in Linguistics, and founding director of the Program in Cognitive Science at Princeton University. Adam Lerner, PhD Philosophy, Postgraduate Research Associate, Princeton 2018. From 2018, Assistant Professor/Faculty Fellow in the Center for Bioethics at New York University. Member of the [Princeton Social Neuroscience Lab](http://psnlab.princeton.edu/).] “Generic Generalizations.” Stanford Encyclopedia of Philosophy. April 24, 2016. <https://plato.stanford.edu/entries/generics/> TG

1. Generics and Logical Form

In English, generics can be expressed using a variety of syntactic forms: bare plurals (e.g., “tigers are striped”), indefinite singulars (e.g., “a tiger is striped”), and definite singulars (“the tiger is striped”). However, none of these syntactic forms is dedicated to expressing generic claims; each can also be used to express existential and/or specific claims. Further, some generics express what appear to be generalizations over individuals (e.g., “tigers are striped”), while others appear to predicate properties directly of the kind (e.g., “dodos are extinct”). These facts and others give rise to a number of questions concerning the logical forms of generic statements.

1.1 Isolating the Generic Interpretation

Consider the following pairs of sentences:

(1)a.Tigers are striped.

b.Tigers are on the front lawn.

(2)a.A tiger is striped.

b.A tiger is on the front lawn.

(3)a.The tiger is striped.

b.The tiger is on the front lawn.

The sentence pairs above are prima facie syntactically parallel—both are subject-predicate sentences whose subjects consist of the same common noun coupled with the same, or no, article. However, the interpretation of first sentence of each pair is intuitively quite different from the interpretation of the second sentence in the pair. In the second sentences, we are talking about some particular tigers: a group of tigers in ([1b](https://plato.stanford.edu/entries/generics/#ex1b)), some individual tiger in ([2b](https://plato.stanford.edu/entries/generics/#ex2b)), and some unique salient or familiar tiger in ([3b](https://plato.stanford.edu/entries/generics/#ex3b))—a beloved pet, perhaps. In the first sentences, however, we are saying something general. There is/are no particular tiger or tigers that we are talking about.

The second sentences of the pairs receive what is called an existential interpretation. The hallmark of the existential interpretation of a sentence containing a bare plural or an indefinite singular is that it may be paraphrased with “some” with little or no change in meaning; hence the terminology “existential reading”. The application of the term “existential interpretation” is perhaps less appropriate when applied to the definite singular, but it is intended there to cover interpretation of the definite singular as referring to a unique contextually salient/familiar particular individual, not to a kind.

There are some tests that are helpful in distinguishing these two readings. For example, the existential interpretation is upward entailing, meaning that the statement will always remain true if we replace the subject term with a more inclusive term. Consider our examples above. In ([1b](https://plato.stanford.edu/entries/generics/#ex1b)), we can replace “tiger” with “animal” salva veritate, but in ([1a](https://plato.stanford.edu/entries/generics/#ex1a)) we cannot. If “tigers are on the lawn” is true, then “animals are on the lawn” must be true. However, “tigers are striped” is true, yet “animals are striped” is false. ([1a](https://plato.stanford.edu/entries/generics/#ex1a)) does not entail that animals are striped, but ([1b](https://plato.stanford.edu/entries/generics/#ex1b)) entails that animals are on the front lawn (Lawler 1973; Laca 1990; Krifka et al. 1995).

Another test concerns whether we can insert an adverb of quantification with minimal change of meaning (Krifka et al. 1995). For example, inserting “usually” in the sentences in ([1a](https://plato.stanford.edu/entries/generics/#ex1a)) (e.g., “tigers are usually striped”) produces only a small change in meaning, while inserting “usually” in ([1b](https://plato.stanford.edu/entries/generics/#ex1b)) dramatically alters the meaning of the sentence (e.g., “tigers are usually on the front lawn”). (For generics such as “mosquitoes carry malaria”, the adverb “sometimes” is perhaps better used than “usually” to mark off the generic reading.)

#### It applies to “medicines” – 1] upward entailment test – “reduce intellectual property protections for medicines” doesn’t entail reducing protections for aids, because it doesn’t prove that we should derestrict other beneficial tech, 2] adverb test – member nations “ought to usually reduce intellectual property protections for medicines” doesn’t substantially change resolutional meaning, 3] predicate level – the rez is an individual level predicate not a stage level because moral obligations in ought statements are long-lasting as opposed to fleeting phases. C/a precision ow.

#### Violation – they only defend \_\_\_\_

#### Vote neg:

#### 1] Limits – you can pick anything from COVID vaccines to HIV/AIDS to random biotech to insulin treatments and there’s no universal disad since each one has a different function and implication for health, tech, and relations – explodes neg prep and leads to random medicine of the week affs which makes cutting stable neg links impossible. PICs don’t solve – it’s absurd to say neg potential abuse justifies the aff being flat out not T, which leads to a race towards abuse, AND if pics are as abusive as they say 1AR theory checks bad. Limits key to reciprocal engagement since they create a caselist for neg prep.

#### 2] TVA – read the aff as an advantage to a whole rez aff. S

## 3

**Permissibility negates – the word ought in the resolution indicates an obligation so they have to prove the existence of one. Ethics must be derived a priori.**

#### 1] Is/Ought Gap – experience in the phenomenal world only tells us what is since we can only perceive what is, not what ought to be. But it’s impossible to derive an ought from descriptive premises, so there needs to be additional a priori premises within the noumenal world to make a moral theory.

#### The existence of extrinsic goodness requires unconditional human worth—that means we must treat others as ends in themselves.

Korsgaard ’83 (Christine M., “Two Distinctions in Goodness,” The Philosophical Review Vol. 92, No. 2 (Apr., 1983), pp. 169-195, JSTOR) OS/Recut Lex AKu \*brackets for gendered language

The argument shows how Kant's idea of justification works. It can be read as a kind of regress upon the conditions, starting from an important assumption. The assumption is that when a rational being makes a choice or undertakes an action,[they] he or she supposes the object to be good, and its pursuit to be justified. At least, if there is a categorical imperative there must be objectively good ends, for then there are necessary actions and so necessary ends (G 45-46/427-428 and Doctrine of Virtue 43-44/384-385). In order for there to be any objectively good ends, however, there must be something that is unconditionally good and so can serve as a sufficient condition of their goodness. Kant considers what this might be: it cannot be an object of inclination, for those have only a conditional worth, "for if the inclinations and the needs founded on them did not exist, their object would be without worth" (G 46/428). It cannot be the inclinations themselves because a rational being would rather be free from them. Nor can it be external things, which serve only as means. So, Kant asserts, the unconditionally valuable thing must be "humanity" or "rational nature," which he defines as "the power set to an end" (G 56/437 and DV 51/392). Kant explains that regarding your existence as a rational being as an end in itself is a "subjective principle of human action." By this I understand him to mean that we must regard ourselves as capable of conferring value upon the objects of our choice, the ends that we set, because we must regard our ends as good. But since "every other rational being thinks of his existence by the same rational ground which holds also for myself' (G 47/429), we must regard others as capable of conferring value by reason of their rational choices and so also as ends in themselves. Treating another as an end in itself thus involves making that person's ends as far as possible your own (G 49/430). The ends that are chosen by any rational being, possessed of the humanity or rational nature that is fully realized in a good will, take on the status of objective goods. They are not intrinsically valuable, but they are objectively valuable in the sense that every rational being has a reason to promote or realize them. For this reason it is our duty to promote the happiness of others-the ends that they choose-and, in general, to make the highest good our end.

#### Practical reason is inescapable - Any moral rule faces the problem of regress – I can keep asking “why should I follow this.” Regress collapses to skep since no one can generate obligations absent grounds for accepting them. Only reason solves since asking “why reason?” requires reason to do in the first place which concedes its authority.

### Offense

#### 1] Patents protect private companies.

Na 19 [Blake Na, "Protecting Intellectual Property Rights in the Pharmaceutical Industry", Chicago-Kent | Journal of Intellectual Property, 4-19-2019, https://studentorgs.kentlaw.iit.edu/ckjip/protecting-intellectual-property-rights-in-the-pharmaceutical-industry/, accessed: 8-24-2021.] //Lex VM

Patent Rights A pharmaceutical company may apply for a patent from the PTO at any time in the development lifetime of a drug.[12] A drug is patentable if it is non-obvious, new, and useful.[13] The drug must be non-obvious when comparing the drug with another previously invented drug, i.e., it does not bring the same type of information as the other drugs. The drug must also not exist, and it must have a purpose. Intellectual property rights, especially patent rights, are the foundation of the pharmaceutical industry. The industry heavily depends on the future profits which innovation (and as a result, exclusivity) enable. Drug patents grant the originator company to market exclusivity for a fixed term of 20 years from the patent’s original filing date. By giving this 20-year patent term in which the government cannot regulate the price, market exclusivity allows pharmaceutical companies to have a monopoly over the market. To maximize their profit, pharmaceutical companies work on extending the exclusivity of a drug. For example, AbbVie extended the manufacturing exclusivity of Humira by delaying generic companies from manufacturing generic entrants until 2023. The market exclusivity can be lengthened anywhere between 180 days to 7 years. Thus, due to efforts to derive profits from patents, pharmaceutical companies’ patents contribute to roughly 70-80 percent of their overall revenues. Patents in the pharmaceutical industry are normally referred to as their product portfolio and are the most effective method for protecting innovation and creating significant returns on investments. Accordingly, as mentioned above, patents help in recouping costs related to research, development, and marketing of a drug. Patents not only help pharmaceutical companies recoup investments, they can also act as a shield against infringement claims. Strong patent protection can safeguard drugs from potential infringers. Without consent from the patentee, other competing companies cannot use, make, or distribute the invention. However, because a drug can be easily imitated by competitors, bringing an infringement suit can also protect a patentee’s rights. Recently, DUSA Pharmaceuticals, Inc.—an arm of the Indian pharmaceutical company Su Pharma and ranked among the top 50 global Pharma Companies—was recently granted injunctive relief from a U.S. court against Biofrontera Inc. in a patent infringement case[14]. The court’s order prohibited Biofrontera from making use of information, including sales data, marketing data, technical information, and unpublished clinical data, of DUSA Pharmaceuticals[15]. Although bringing an infringement suit is a valuable remedial measure for patentees, pharmaceutical companies often face difficulty with the high costs and uncertainty of litigation

#### That negates – A] Promise breaking – states promised legally binding IP protections to companies who might not have otherwise developed medicines – the aff is a unilateral violation of that contract. B] That’s a form of restricting the free economic choices of individuals.

#### 2] IP is a reflection of our will and a form of property.

Merges 11 [Merges, Robert P. "Will and Object in the World of IP." Justifying Intellectual Property, Cambridge, Harvard UP, 2011, pp. 76-78. ISBN: 0674049489,9780674049482. Found on Libgen.] //Lex VM

It is clear enough at this point that Kant thought reliable expectations about ongoing possession of objects enables something positive to take place. Stable possession permits the imprinting of some aspect of a person, what Kant called his will, onto objects so as to enable the person to more fully flourish. Though nuances abound, Kant’s basic idea regarding the will24 is simple enough: Will is that aspect of a person which decides to, and wants to, act on the world.25 It has three distinctive qualities: it is personal, autonomous, and active. It is highly individual, a function of each person’s preferences and desires; Lewis White Beck says that will is “bent upon the satisfaction of some arbitrary purpose.” It is this aspect or feature of ourselves that we imprint or stamp on the world through our choices and the resulting actions that carry out or manifest these choices. Right here, in this foundational element, we see a radically individualistic and autonomous view of humans. Although this is balanced by a universalizing, transpersonal sense of reason in other parts of his philosophy,26 a highly individual will is nonetheless central to Kant’s view of human thought and action, and thus an essential aspect of what he thought it means to be human.27 will and object in the world of ip. It is tempting to get caught up in the terminology and conceptual complexity of Kant’s ideas of persons, will, and objects. To prevent that happening, it seems wise at this point to talk about some specific examples. How exactly does Kantian autonomy work? What does it look like in the context of IP rights? After we have a better grasp of these ideas, and of how they relate to Kant’s rationale for property, we can turn to an equally important topic: the limits on individual autonomy that Kant built into his theory. Our earlier example of Michelangelo showed how stable possession is required for a creator to fully work his will on a found object— in that case, a block of marble. The same basic logic applies in all sorts of cases. Individual farmers and landowners generate and then bring to life a vision for the lands they work on;28 inventors transform off- the- shelf materials into prototypes, rough designs, and finished products; and artists work in media such as paint and canvas, paper and pen, textiles and wood, keyboard and iPad, and so on, to give life to a concept or mental image. Wherever personal skill and judgment are brought to bear on things that people inherit or find, we see evidence of the Kantian process of will imprinting itself on objects. It even happens when the objects at hand are themselves intangible. A composer working out a new instance of a traditional form— a fugue or symphony, blues song or tone poem— is working on found objects just as surely as the farmer or inventor. Even in our earlier example, some of the objects that Michelangelo works on in the course of carving his sculpture are intangible: received conventions about how to depict an emotion; traditional groupings of figures in a religious set piece, such as the Pieta; or accepted norms about how to depict athletic grace or youthful energy. He may take these pieces of the cultural tableau and refine them, or he may subtly resist or transform them. However he handles them, these conventions are just as much objects in his hands as the marble itself.29 As with found physical objects, extended possession of these objects- intransformation is required to fully apply the creator’s skill and judgment. And because of this, Kantian property rights come into play with intangible objects as well. Let me say a word about this complex, and perhaps controversial, possession of intangible objects. It has often been argued that this feature of IP, the control of copies of an intangible work, constitutes a form of “artificial scarcity,”30 that it runs counter to an ethically superior regime where information is shared freely— and is maybe even counter to the nature of information, which, some say, “wants to be free.”31 According to Kant, all property rights have this element of artifice, because they define a conceptual type of possession. Property is not just a matter of physical contact between person and object; it describes a relationship that is deeper and goes well beyond the basic acts of grasping and holding. I can hear one objection to this right away. Yes, Kant speaks of legal ownership as a special relation between a person and an object. But, the objection might run, in his writings he refers only to physical objects, for example, an apple (à la Locke). So maybe the ownership relation is limited to that sort of thing? No. I give no weight to the fact that Kant uses only examples of tangible, physical property in most of the sections of the Doctrine of Right (DOR).32 Kant describes an additional type of possession that makes it crystal clear that the idea is not in any way limited to physical things—the expectation of future performance under a contract. He posits that one could not properly be said to “possess” a right to performance under an executory contract (one that has been signed or agreed to, but not yet performed) unless “I can maintain that I would have possession . . . even if the time of the performance is yet to come.”33 With that legal relation established, however, “[t]he promise of the [promisor] accordingly belongs among my worldly goods . . . , and I can include it under what is mine.”34 The synonymous use of “possession,” “object,” “belonging,” and “mine” in the case of a tangible, physical thing such as an apple and an intangible thing such as a promise of future contractual performance is too clear to require much comment. “Object” is very abstract for Kant, and can of course therefore include IPRs.35

## 4

#### Counterplan text: Member nations of the WTO should \_\_\_\_\_\_ except Saudi Arabia.

#### The US is concerned about Saudi IPR but trade relations are fine now

US Gov 21 [United States Government, Office of the US Trade Representative “2021 Special 301 Report” Published: 2021] [https://ustr.gov/sites/default/files/files/reports/2021/2021%20Special%20301%20Report%20(final).pdf] || SM

Saudi Arabia remains on the Priority Watch List in 2021.

Ongoing Challenges and Concerns

Saudi Arabia was placed on the Priority Watch List in 2019 for failing to take action against the rampant satellite and online piracy made available by illicit pirate service beoutQ, continued lack of effective protection of intellectual property (IP) for pharmaceutical products, and long-standing concerns regarding enforcement against counterfeit and pirated goods within the country. BeoutQ ceased operations in August 2019. The Saudi Authority for Intellectual Property (SAIP) continued to take steps to improve IP protection, enforcement, and awareness throughout Saudi Arabia in 2020. However, concerns remain over actions by the Saudi Arabia Food and Drug Authority (SFDA), which the Minister of Health oversees, that are contrary to Saudi Arabia’s public statements in paragraph 261 of the Report of the Working Party on the Accession of the Kingdom of Saudi Arabia to the World Trade Organization. Starting in 2016, SFDA has been granting marketing approval to domestic companies for subsequent versions of registered products, without requiring the submission of data that meets the same requirements applied to the initial applicant, despite the period of protection provided to the initial applicant by Saudi regulations. SFDA’s continued actions and the lack of redress for affected companies have intensified concerns. Furthermore, the National Unified Procurement Company for Medical Supplies, also overseen by the Minister of Health, reportedly awarded national tenders to some of these domestic companies for the affected products.

#### The plan stifles Saudi innovation by sending investors away which hurts US Saudi Relations.

Stevens 17 [Stevens, Philip. “Saudi Missteps on Intellectual Property Will Hold Back Its Economy.” *TheHill*, 17 Sept. 2017, thehill.com/opinion/international/351074-saudis-missteps-on-intellectual-property-will-hold-back-its-economy?rl=1., *Philip Stevens is director of Geneva Network, a UK-based research organization focusing on trade and innovation issues.*] //Lex AKu

Saudi Arabian policymakers know that increasing knowledge-based sectors is the key to sustainable growth as their economy transitions away from oil. “You cannot be depending on oil in a world where the knowledge economy is the driver of economic development — manufacturing is 20th century,” Fahd Al-Rasheed, CEO of King Abdullah Economic City, said in June. Vision 2030, the plan to diversify the Saudi economy, also sees a big role for knowledge-based industries. This makes sense. In the U.S., knowledge-intensive goods and services from sectors including biotech, chemicals, entertainment and information technology now make up over half of all U.S. exports, reversing the situation of only 40 years ago when manufacturing dominated. Advanced Asian economies — Japan, the Republic of Korea, Advanced Asian economies — Japan, the Republic of Korea, Singapore and Taiwan — have also taken this path, moving over recent decades from agriculture to manufacturing to knowledge-based economies. Few countries have developed thriving knowledge-based industries purely from domestic resources. Scientific knowledge, technological know-how and the required research and development capital are dispersed globally. Gone are the days when one R&D company, for example, the industrial behemoth General Electric or the biopharmaceutical major Merck, created products in-house from start to finish. Today, innovation is a result of collaboration between multinational companies, small companies, start-ups, academia and the public sector at all stages of the R&D cycle, often across borders. Saudi Arabia’s challenge is to become a meaningful participant in this new world of networked innovation. It must attract innovative companies to its shores, bringing with them the capital, skills and technological know-how the Kingdom may be missing. The potential prize is enormous: China now captures more Foreign Direct Investment in R&D than the U.S. thepharmaceuticals sector leads the way with investments, totaling $1.6bn between 2010 and 2015, according to FDI Markets. The Kingdom has some advantages that could direct it down the R&D path. It has a young population, a growing base of science graduates and relatively high investment in health care, internet and other forms of infrastructure. Tax incentives, and investment in education and information technology will only go so far, though. Above all, foreign investors need certainty over their intellectual property rights, including clearly defined and easily enforceable patent rights. If this protection is strong, companies will be more likely to invest in local R&D facilities, or enter into partnerships with local companies. New products will be launched early into Saudi Arabia, as innovators will have no fear of their valuable IP rights being compromised. Saudi Arabia has the intellectual property basics in place, in line with its World Trade Organization commitments. In fact, the U.S. Chamber of Commerce’s 2017 International IP index noted Saudi Arabia has a “strong patenting environment.” Yet, recent developments risk derailing this progress. Just months after granting a patent for a new medicine to a company based in the United States, the Saudi Food and Drug Administration (SFDA) reneged on the deal.The Saudi patent for Hepatitis drug Daclatasvir was granted by the Patent Office of the Gulf Cooperation council (which encompasses Saudi Arabia) to BMS in Dec 2016. Nevertheless, the SFDA granted marketing approval to a generic version manufactured Saudi company in May 2017, despite the BMS patent still being in force. Granting marketing approval to generic copies of the product in this way is arguably a breach of patent rights. Likewise, the SDFA has also recently allowed local companies to manufacture generic versions of another medicine developed by another U.S. biotech company — potentially contrary to World Trade Organization rules surrounding the protection of clinical test data, itself an important intellectual property right. Saudi IP law allows for 5-year period in which generic companies may not use the clinical trial data submitted to regulatory authorities by originator drug manufacturers to gain marketing approval ("data exclusivity"). Gilead Sciences was granted marketing approval by the SFDA in 2014 for its product Sofosbuvir. The SFDA has subsequently granted marketing approval for generic versions of this product made by a Saudi and Egyptian company — within the 5-year data exclusivity window. This could be a breach of Saudi data exclusivity regulations. Taken together, such actions send a hostile message to foreign investors that their valuable IP rights are not safe in Saudi Arabia. Such hostility will undermine Saudi’s economic ambition by scaring off valuable investment and skills. They also act as an irritant to U.S.-Saudi relations, with the Trump administration indicating a higher prioritization of IP enforcement amongst its trading partners. Meanwhile, regional neighbors such as the UAE and Asian competitors such as Singapore are seizing the opportunities presented by the globalization of innovation, which drive increasing proportions of their economic growth. Saudi Arabia could emerge as a global competitor in knowledge-based industries. It’s an achievable vision, but it requires the policy details to be right, not just the rhetoric.

#### US Saudi Coop key to prevent nuclear proliferation

Emily B. Landau and Shimon Stein 18 [Landau is senior research associate at the Institute for National Security Studies, where she is also director of the Arms Control and Regional Security Project. Stein was Israel's ambassador to Germany from 2001 to 2007. Previously, he participated in the Arms Control and Regional Security working group, as well as negotiations of the Comprehensive Nuclear Test Ban Treaty, and served as head of the Regional Security, Arms Control, and Nonproliferation Department at the Israel Ministry of Foreign Affairs.], 12-4-2018, "Can the United States Prevent Saudi Arabia from Getting Nuclear Weapons?," National Interest, <https://nationalinterest.org/feature/can-united-states-prevent-saudi-arabia-getting-nuclear-weapons-37812> {OS}

The United States has always been very concerned about the proliferation risks involved in nuclear cooperation, and in 2008 it was able to achieve a memorandum of understanding with Saudi Arabia on nuclear energy cooperation whereby the latter pledged to acquire nuclear fuel from international markets, rather than producing it indigenously. But ten years later, it seems that Saudi Arabia no longer views itself as bound by that understanding. The current challenge for the United States is how to insist on what is known as a 123 agreement with Saudi Arabia, meaning that the agreement explicitly denies Saudi Arabia the right to work on sensitive nuclear technologies (enrichment capabilities and plutonium reprocessing), without driving it into the hands of other nuclear suppliers, such as Russia, China and South Korea, that may be less worried about ensuring these restrictions.¶ There are concerns that the Trump administration might be willing to concede to Saudi Arabia sensitive capabilities, and the fact that it is not willing to divulge information regarding the status of the negotiations does not bode well in this regard. The administration is keenly aware of the link to Iran’s nuclear posture, and that the Joint Comprehensive Plan of Action (JCPOA) set a very negative precedent for nuclear cooperation with other states when it legitimized Iran’s enrichment capabilities. While Iran must cap its stockpile of enriched uranium for the duration of the deal, it is allowed—under the explicit terms of the deal—to work on R&D into an entire range of advanced centrifuges. Iran has plans to install and operate these centrifuges eleven years into the deal. There is a real question of how these capabilities can be denied to states like Saudi Arabia who are in good standing with the NPT, whereas Iran—who blatantly violated the nonproliferation treaty—was granted the right to continue with these dangerous enrichment-related activities.

#### Saudi prolif draws in India and Pakistan – goes nuclear

Edelman 11—Fellow at the Center for Strategic and Budgetary Assessments. Former Undersecretary for Defense—AND—Andrew Krepinevich—President of the Center for Strategic and Budgetary Assessments—AND—Evan Montgomery—Research Fellow at the Center for Strategic and Budgetary Assessments (Eric, The dangers of a nuclear Iran, FA 90;1, http://www.csbaonline.org/wp-content/uploads/2010/12/2010.12.27-The-Dangers-of-a-Nuclear-Iran.pdf)

There is, however, at least one state that could receive significant outside support: Saudi Arabia. And if it did, proliferation could accelerate throughout the region. Iran and Saudi Arabia have long been geopolitical and ideological rivals. Riyadh would face tremendous pressure to respond in some form to a nuclear-armed Iran, not only to deter Iranian coercion and subversion but also to preserve its sense that Saudi Arabia is the leading nation in the Muslim world. The Saudi government is already pursuing a nuclear power capability, which could be the first step along a slow road to nuclear weapons development. And concerns persist that it might be able to accelerate its progress by exploiting its close ties to Pakistan. During the 1980s, in response to the use of missiles during the Iran-Iraq War and their growing proliferation throughout the region, Saudi Arabia acquired several dozen css-2 intermediate-range ballistic missiles from China. The Pakistani government reportedly brokered the deal, and it may have also oªered to sell Saudi Arabia nuclear warheads for the css-2s, which are not accurate enough to deliver conventional warheads eªectively. There are still rumors that Riyadh and Islamabad have had discussions involving nuclear weapons, nuclear technology, or security guarantees. This “Islamabad option” could develop in one of several different ways. Pakistan could sell operational nuclear weapons and delivery systems to Saudi Arabia, or it could provide the Saudis with the infrastructure, material, and technical support they need to produce nuclear weapons themselves within a matter of years, as opposed to a decade or longer. Not only has Pakistan provided such support in the past, but it is currently building two more heavy-water reactors for plutonium production and a second chemical reprocessing facility to extract plutonium from spent nuclear fuel. In other words, it might accumulate more fissile material than it needs to maintain even a substantially expanded arsenal of its own. Alternatively, Pakistan might oªer an extended deterrent guarantee to Saudi Arabia and deploy nuclear weapons, delivery systems, and troops on Saudi territory, a practice that the United States has employed for decades with its allies. This arrangement could be particularly appealing to both Saudi Arabia and Pakistan. It would allow the Saudis to argue that they are not violating the npt since they would not be acquiring their own nuclear weapons. And an extended deterrent from Pakistan might be preferable to one from the United States because stationing foreign Muslim forces on Saudi territory would not trigger the kind of popular opposition that would accompany the deployment of U.S. troops. Pakistan, for its part, would gain financial benefits and international clout by deploying nuclear weapons in Saudi Arabia, as well as strategic depth against its chief rival, India. The Islamabad option raises a host of difficult issues, perhaps the most worrisome being **how India would respond**. Would it **target Pakistan**’s weapons in Saudi Arabia with its own conventional or nuclear weapons? How would this expanded nuclear competition influence **stability** during a crisis in either the Middle East or South Asia? Regardless of India’s reaction, any decision by the Saudi government to seek out nuclear weapons, by whatever means, would be **highly destabilizing**. It would increase the incentives of other nations in the Middle East to pursue nuclear weapons of their own. And it could increase their ability to do so by eroding the remaining barriers to nuclear proliferation: each additional state that acquires nuclear weapons **weakens the nonprolif**eration **regime**, even if its particular method of acquisition only circumvents, rather than violates, the npt. Were Saudi Arabia to acquire nuclear weapons, the Middle East would count three nuclear-armed states, and perhaps more before long. It is unclear how such an n-player competition would unfold because most analyses of nuclear deterrence are based on the U.S.- Soviet rivalry during the Cold War. It seems likely, however, that the interaction among three or more nuclear-armed powers would be more prone to **miscalc**ulation and **escalation** than a bipolar competition. During the Cold War, the United States and the Soviet Union only needed to concern themselves with an attack from the other.Multipolar systems are generally considered to be less stable than bipolar systems because coalitions can shift quickly, upsetting the balance of power and creating incentives for an attack. More important, emerging nuclear powers in the Middle East might not take the costly steps necessary to preserve regional stability and avoid a nuclear exchange. For nuclear-armed states, **the bedrock of deterrence** is the knowledge that each side has a secure second-strike capability, so that no state can launch an attack with the expectation that it can wipe out its opponents’ forces and avoid a devastating retaliation. However, **emerging nuclear powers might not invest in** expensive but **survivable capabilities** such as hardened missile silos or submarinebased nuclear forces. Given this likely vulnerability, the close proximity of states in the Middle East, and the very short flight times of ballistic missiles in the region, any new nuclear powers might be compelled to “launch on warning” of an attack or even, during a crisis, to use their nuclear forces preemptively. Their governments might also delegate launch authority to lower-level commanders, heightening the possibility of miscalculation and escalation. Moreover, if early warning systems were not integrated into robust command-and-control systems, the risk of an unauthorized or accidental launch would increase further still. And without sophisticated early warning systems, a nuclear attack might be unattributable or attributed incorrectly. That is, assuming that the leadership of a targeted state survived a first strike, it might not be able to accurately determine which nation was responsible. And this uncertainty, when combined with the pressure to respond quickly, would create a significant risk that it would retaliate against the wrong party, potentially triggering **a regional nuclear war.** Most existing nuclear powers have taken steps to protect their nuclear weapons from unauthorized use: from closely screening key personnel to developing technical safety measures, such as permissive action links, which require special codes before the weapons can be armed. Yet there is no guarantee that emerging nuclear powers would be willing or able to implement these measures, creating a significant risk that their governments might lose control over the weapons or nuclear material and that nonstate actors could gain access to these items. Some states might seek to mitigate threats to their nuclear arsenals; for instance, they might hide their weapons. In that case, however, a single intelligence compromise could leave their weapons vulnerable to attack or theft.